Autolus Appoints John Johnson to Their Board of Directors

On Wednesday, September 15, Autolus announced (press release) John Johnson’s appointment as non-executive chairman of their Board of Directors. Additionally, Martin Murphy, who previously served as chairman, will continue to serve as a non-executive board member. Below, Celltelligence provides insights on Autolus’s leadership strategy to prepare for obe-cel’s (CD19 CAR-T, formerly AUTO1) commercial launch, while commenting on the potential acquisition of Autolus.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.